Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

Hepatology

Volumn 54, Issue 2, 2011, Pages 532-540

  Yoshida, Haruhiko ^a   Shiratori, Yasushi ^b   Kudo, Masatoshi ^c   Shiina, Shuichiro ^a   Mizuta, Toshihiko ^d   Kojiro, Masamichi ^e   Yamamoto, Kyosuke ^f   Koike, Yukihiro ^g   Saito, Kenichi ^h   Koyanagi, Nozomu ^h   Kawabe, Takao ^a   Kawazoe, Seiji ⁱ   Kobashi, Haruhiko ^b   Kasugai, Hiroshi ^j   Osaki, Yukio ^k   Araki, Yasuyuki ^l   Izumi, Namiki ^m   Oka, Hiroko ⁿ   Tsuji, Kunihiko ^o   Toyota, Joji ^p   Seki, Toshihito ^q   Osawa, Toshiya ^r   Masaki, Naohiko ^s   Ichinose, Masao ^t   Seike, Masataka ^u   Ishikawa, Akihisa ^v   Ueno, Yoshiyuki ^w   Tagawa, Kazumi ^x   Kuromatsu, Ryoko ^y   Sakisaka, Shotaro ^z   Ikeda, Hiroshi ^aa   Kuroda, Hidekatsu ^ab   Kokuryu, Hiroyuki ^ac   Yamashita, Tatsuya ^ad   Sakaida, Isao ^ae   Katamoto, Tetsuo ^af   Kikuchi, Kentaro ^ag   Nomoto, Minoru ^ah   Omata, Masao ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAGA UNIVERSITY   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f Takagi Hospital   (Japan)

^g The Mutualaid Association of Public School Teachers)   (Japan)

^h EISAI CO LTD   (Japan)

ⁱ Saga Prefectural Hospital Koseikan   (Japan)

^j OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^k OSAKA RED CROSS HOSPITAL   (Japan)

^l HIROSHIMA CITY HOSPITAL   (Japan)

^m MUSASHINO RED CROSS HOSPITAL   (Japan)

ⁿ OSAKA CITY GENERAL HOSPITAL   (Japan)

^o TEINE KEIJINKAI HOSPITAL   (Japan)

^p Sapporo Kosei General Hospital   (Japan)

^q KANSAI MEDICAL UNIVERSITY   (Japan)

^r OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^s NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^t WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^u OITA UNIVERSITY   (Japan)

^v Hitachi   (Japan)

^w TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^x MITSUI MEMORIAL HOSPITAL   (Japan)

^y KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^z FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^aa KURASHIKI CENTRAL HOSPITAL   (Japan)

^ab IWATE MEDICAL UNIVERSITY   (Japan)

^ac SHIZUOKA GENERAL HOSPITAL   (Japan)

^ad KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^ae YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^af JR Tokyo General Hospital   (Japan)

^ag TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ah NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFP LENS CULINARIS AGGLUTININ FRACTION 3; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FARNOQUINONE; MENATETRENONE; PLACEBO; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT REFUSAL; TUMOR ABLATION; UNSPECIFIED SIDE EFFECT;

AGED; CARCINOMA, HEPATOCELLULAR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; VITAMIN K 2; VITAMINS;

EID: 79960744370     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24430     Document Type: Article

References (31)

1. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141: 330-339.
2. Ibrahim S, Roychowdhury A, Hean TK. Risk factors for intrahepatic recurrence after hepatectomy for hetocellular carcinoma. Am J Surg 2007; 194: 17-22.
3. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. HEPATOLOGY 2006; 44: 1518-1527.
4. Ercolani G, Grazi GL, Ravaioli M, Gaudio MD, Gardini A, Cescon M, et al. Liver resection for hepatocellular varcinoma on cirrhosis. Ann Surg 2003; 237: 536-543.
5. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
6. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. HEPATOLOGY 1997; 25: 87-92.
7. Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000; 135: 1456-1459.
8. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. HEPATOLOGY 2006; 44: 891-895.
9. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-361.
10. Koike K, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001; 91: 561-569.
11. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. HEPATOLOGY 1995; 22: 876-882.
12. Bouzahzah B, Nishikawa Y, Simon D, Carr BI. Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep 40: inhibitory actions of vitamin K. J Cell Physiol 1995; 165: 459-467.
13. Otsuka M, Kato N, Shao R, Hoshida Y, Ijichi H, Koike Y, et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. HEPATOLOGY 2004; 40: 243-251.
14. Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor κB activation. Clin Cancer Res 2007; 13: 2236-2245.
15. Kaneda M, Zhang D, Bhattacharjee R, Nakahama K, Arii S, Morita I. Vitamin K2 suppresses malignancy of HuH7 hepatoma cells via inhibition of connexin 43. Cancer Lett 2008; 263: 53-60.
16. Sakai I, Hashimoto S, Yoda M, Hida T, Ohsawa S, Nakajo S, Nakaya K. Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun 1994; 205: 1305-1310.
17. Yaguchi M, Miyazawa K, Otawa M, Katagiri T, Nishimaki J, Uchida Y, et al. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 1998; 12: 1392-1397.
18. Nishimaki J, Miyazawa K, Yaguchi M, Katagiri T, Kawanishi Y, Toyama K, et al. Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation. Leukemia 1999; 13: 1399-1405.
19. Orimo H, Shiraki M, Tomita A, Morii A, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab 1998; 16: 106-112.
20. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: 515-521.
21. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporosis Int 2007; 18: 963-972.
22. Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, et al. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 2009; 27: 66-75.
23. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al. The effect of menatetrenone, a vitamin K2 analogue, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer 2006; 106: 867-872.
24. Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007; 22: 518-522.
25. Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 2073-2077.
26. The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma. Hepatol Res 2010; 40: 6-7.
27. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-1500.
28. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
29. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J Roy Stat Soc A 1994; 157: 357-416.
30. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55: 853-857.
31. Huisse MG, Leclercq M, Belghiti J, Flejou JF, Suttie JW, Bezeaud A, et al. Mechanism of the abnormal vitamin K-dependent γ-carboxylation process in human hepatocellular carcinomas. Cancer 1994; 74: 1533-1541.